Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet's disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study

CONCLUSIONS: As ADA is effective for refractory intestinal BD with few safety concerns in real-world situations, it is a potential treatment option for Korean patients with intestinal BD.PMID:37491721 | DOI:10.3904/kjim.2022.394

Source: The Korean Journal of Internal Medicine - July 26, 2023 Category: Internal Medicine Authors: Seung Bum Lee Hee Seung Hong Chang Kyun Lee Bo-In Lee Sol Kim Seong-Joon Koh Hosun Yu Jung-Bin Park Sung Wook Hwang Byong Duk Ye Suk-Kyun Yang Sang Hyoung Park IBD Research Group of the Korean Association for the Study of Intestinal Diseases (KASID) Source Type: research